COMPANY

R3 Vascular

HQ: Mountain View, CA source · r3vascular.com ↗

Location: Mountain View, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Chronic Limb-Threatening Ischemia Critical Limb-Threatening Ischemia Critical Limb Ischemia Critical Lower Limb Ischemia Peripheral Arterial Disease Atherosclerotic Lesion Lower Extremity Ischemia Lower Extremity Claudication MAGNITUDE BRS Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold

3Trials (company is sponsor)

Timeline

Apr 11, 2025 Trial start Not phased (device or behavioral study): Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease source ↗
Mar 4, 2024 Trial start Not phased (device or behavioral study): Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia source ↗
Aug 17, 2021 Trial start Not phased (device or behavioral study): Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Not phased · Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia · NCT06075940
Dec 31, 2026 (ESTIMATED) · Not phased · Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease · NCT04912323
Mar 1, 2028 (ESTIMATED) · Not phased · Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease · NCT06071429

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT06071429	Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease	Not phased (device or behavioral study)	Recruiting	Apr 11, 2025	Mar 1, 2028 (estimated)
NCT06075940	Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia	Not phased (device or behavioral study)	Recruiting	Mar 4, 2024	Dec 31, 2026 (estimated)
NCT04912323	Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease	Not phased (device or behavioral study)	Recruiting	Aug 17, 2021	Dec 31, 2026 (estimated)